Kiromic BioPharma Inc (KRBP)

[moondogaz]

This can be enzc on steroids

[81vette]

$28,000 ask slap @hod .264,getting some attention now

[moondogaz]

Low freekn float.

[81vette]

huge demand again,hang on tight,demand/supply is what places value on everything in the world!!!

[moondogaz]

Took a starter.

[moondogaz]

My dd...in chat gpt....is telling me..to do more dd.. lol.

[moondogaz]

Sleep well.... dream big.

[moondogaz]

I was in on enzc at .008.

[moondogaz]

I'm all about diamonds in the rough.

[moondogaz]

I'm already doing my dd.

[moondogaz]

Just found this

[81vette]

after mkt and pre mkt mon could get fun

[81vette]

$110,000 bid,ppl have to be losing their minds with excitement seeing the demand vs supply

[81vette]

480k demand @.2271,natural ask buys would put us to $15.00 lol,lets see if last of debt gets paid off or if its done

[81vette]

insider transactions up 300%,they have 20% of their skin in the float,they want KRBP to go up too!!

[81vette]

Filer #Shares Filed For date #Previous %Chg Prev. Date
13F-HR
WealthTrust Axiom 10.00 k 30 Jan 23 31 Dec 22 10.00 k 0% 30 Sep 22
13F-HR
Proequities 0.00 30 Jan 23 31 Dec 22 0.00 30 Sep 22
SC 13G
Empery Asset Management 491.55 k 12 Jan 23 31 Dec 22 0.00 +8% 30 Sep 22
SC 13G
Sabby Volatility Warrant Master Fund 1.82 mm 4 Jan 23 31 Dec 22 0.00 +8% 30 Sep 22
13F-HR
Proequities 0.00 15 Nov 22 30 Sep 22 0.00 30 Jun 22
13F-HR
Citadel Advisors 39.87 k 14 Nov 22 30 Sep 22 11.26 k +254% 30 Jun 22
13F-HR
Morgan Stanley 1.20 k 14 Nov 22 30 Sep 22 1.20 k 0% 30 Jun 22
13F-HR
Zeke Capital Advisors 107.00 k 14 Nov 22 30 Sep 22 107.00 k 0% 30 Jun 22
13F-HR
Two Sigma Securities 11.05 k 14 Nov 22 30 Sep 22 49.87 k -78% 30 Jun 22
13F-HR
Wells Fargo & Co. 75.00 14 Nov 22 30 Sep 22 42.00 +79% 30 Jun 22

[81vette]

Largest owners Shares Value Change
Zeke Capital Advisors 107.00 k $31.00 k 0.0%
Redmond Asset Management 41.76 k $12.00 k -5.9%
Geode Capital Management 40.96 k $11.00 k 0.0%
Citadel Advisors 39.87 k $12.00 k +102.4%
UBS UBS Group AG - Registered Shares 18.51 k $5.00 k +259.1%
Two Sigma Securities 11.05 k $3.00 k -77.8%
Cetera Advisor Networks 10.51 k $3.00 k NEW
WealthTrust Axiom 10.00 k $2.00 k 0.0%
Tower Research Capital 4.87 k $1.00 k -0.9%
PNC PNC Financial Services 4.00 k $1.00 k NEW

[81vette]

yep,a chart like this tells me insiders have told their uncles sisters mothers brothers cousins friends dads that good news is coming,or its a bull trap formed by mms (conspiracy theories explain what ppl dont understand,lol )

[81vette]

accumulation/distribution was -10 last fri,today its -1(crossed to + briefly)great sign that most holders who wanted out are out,today signaled a 5day pps breakout,shouldn't be much longer now as loading continues,float gets bought up and demand exceeds supply. maybe fomo of news over weekend will prevent a fri. selloff,even tho a fri selloff wouldn't be a bad thing as 200ma is @.34 now so it would bring a golden cross even sooner only a matter of time and patience with little risk and high reward

[wickerman]

$KRBP FDA [IND] news will blast her sky high the market cap isn't even $4m and $10m financing is already in the bank just a 15.3m share float and they STILL haven't found this gem.

[81vette]

ppl buy,it doesnt skyrocket,they sell with loss,(good for us)everyday 200ma and macd get closer to breakout signal(some call it churning or consolidation)

[81vette]

40k shares filled on that dip,10k more still to fill,higher highs last 3 days and res. breakout today was my buy more signal

[81vette]

patiently awaiting expected news as institutions/insiders load up

[81vette]

nice bottom grab!!!, A I/crypto stuff blowing up,dont see how it works with cancer but pps does

[81vette]

vol. and pps rising

[Curt D]

Jumped in here with a starter.

[81vette]

.246 will be parabolic,.3525 is 200ma

[81vette]

the debt might be done>https://finance.yahoo.com/news/kiromic-biopharma-arranges-10-million-124800993.html

[81vette]

172k@bid,watch to see if it gets distributed or accumulated as pps flag getting quite pointy/pokey/stabbylooking like its go time,up or down doesnt matter its go go go time for power hour

[81vette]

news coming?>The company is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers.

[81vette]

consolidation since nov.2021,about to breakout over macd buy line 1st time in years!!!

[81vette]

stair stepping higher lows last two days,380,000 short interest,short availability dropping last 3 days,float getting locked up for some reason as accumulation continues

[81vette]

Shares Outstanding 15.84M,Shares Float 15.52M,Institutional Ownership 1.70%,Insider Ownership 6.60%,Short Float 1.43%

[glenn1919]

KRBP..............................https://stockcharts.com/h-sc/ui?s=KRBP&p=W&b=5&g=0&id=p86431144783

[makinezmoney]

$KRBP: Cup n Handle here at 0.22


She could really lift offf on that bullish TA now


GO $KRBP

[subslover]

Anytime bro! This one is getting tons of buys

[Invest-in-America]

THANKS S-L!!!

[subslover]

Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
October 06 2022 - 08:08AM
Business Wire
Alert
Print
Share On Facebook
Company Reiterates Deltacel is Next Clinical Trial Candidate, with Projected Clinical Trial Launch Expected in Q1 2023

Company is Streamlining Operations to Execute Deltacel-Aligned Development Strategy

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces it received validating written feedback on October 4, 2022 from the FDA pursuant to its Type B Pre-IND meeting request regarding its Deltacel™ development strategy.

The purpose of the Pre-IND meeting request was to seek alignment with and to obtain FDA guidance on Kiromic’s proposed development strategy about the chemistry, manufacturing, and controls (CMC), nonclinical studies, and clinical study plan for Deltacel™/KB-GDT for treating subjects with Non-Small Cell Lung Cancer (NSCLC). Kiromic will leverage this FDA Pre-IND written confirmatory feedback and recommendations into a robust IND submission package for a projected clinical trial launch in Q1 2023.

“We are delighted to receive this very productive feedback about Deltacel™/KB-GDT from the FDA, confirming our development strategy for this therapeutic candidate,” stated Pietro Bersani, Chief Executive Officer of Kiromic. “It was a strategic decision to focus on metastatic stage 4 lung cancer as our first indication in addressing solid malignancies, and we are very heartened to be continuing to fulfill our mission to address solid malignancies, which represent more than 90% of all cancers.”

Further reiterating Management’s focus on executing the Deltacel-aligned development strategy, the Company has streamlined its operations and aligned key resources to advance its Deltacel™ product candidate while maintaining its other product candidates Procel™ and Isocel™. As part of that aligned strategy and following a thorough evaluation to maximize operational efficiencies, Kiromic’s management made the difficult yet necessary decision to eliminate 20 positions or approximately 29% of its workforce. The Company believes these key actions and overall strategy align with financing options it is actively pursuing.

“Deltacel™ is our most advanced therapeutic candidate, and its use of allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cells (GDT) is a next-generation solution for patients. As such, this prioritization also mitigates supply-chain challenges associated with a virus-based approach. We believe these advantages will allow us to efficiently establish the platform’s safety and tolerability and build upon Deltacel™’s previously demonstrated preclinical efficacy across multiple indications. With the FDA guidance in hand, we believe we’ve further strengthened our case to align operations with Deltacel™ and deliver value sooner to our shareholders,” commented Bersani.

About Kiromic BioPharma

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid cancers. From its heritage as a cancer vaccine development company, Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. The pipeline development is leveraged through the Company’s proprietary target discovery engine called “DIAMOND.” Kiromic’s DIAMOND is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial

[Triple nickle]

Added again

[Triple nickle]

Added to the stash

[Invest-in-America]

KRBP: Ya want your stock to SOAR??? Well, simply get SUED in Court!!!

[INFINITI]

Looking good here $$$$

[Golden Cross]

Monster Volume

[Golden Cross]

Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline
https://ih.advfn.com/stock-market/NASDAQ/kiromic-biopharma-KRBP/stock-news/88543796/kiromic-biopharma-achieves-milestone-with-timely-c

[Golden Cross]

On watch right now... Caught the high volume the other day on scanner...
A lot of room to run north from here from where it was...

[PennyPusher786]

What you thinking here... trades quite thin from the looks of today's volume vs gains

[Golden Cross]

Outstanding Shares~~~15,585,587~~~~

[Golden Cross]

Over $8 in past 12mo

[Golden Cross]

Kiromic BioPharma is a clinical-stage biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is in the process of developing a multi-indication gamma delta allogeneic T cell therapy treatment platform that exploits the natural potency of gamma delta T cells to target solid cancers. Kiromic is focused on discovering, developing and commercializing novel immuno-oncology therapies through its robust product pipeline, leveraged by DIAMOND® AI, a proprietary target discovery engine where data science meets target identification to dramatically compress the timeline and cost of drug development. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

[Golden Cross]

Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
June 07 2022 - 07:05AM

In Vivo Preclinical Data Expected to Enable Three New IND Applications to Evaluate Company’s Gamma Delta T cell Product Candidates Procel™, Isocel™, and Deltacel™

Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a focus on immuno-oncology, today announces it has entered into a sponsored research agreement (SRA) with Principal Investigator James W. Welsh, M.D. of The University of Texas MD Anderson Cancer Center.

Under the two-year SRA, in vivo preclinical data will be generated from Kiromic’s Gamma Delta T cell (GDT) allogeneic therapies. This SRA is intended to evaluate efficacy and patient safety outcomes to support three new investigational drug (IND) applications to the U.S. Food and Drug Administration (FDA).

“We believe that the SRA will enable us to generate key in vivo data efficiently and swiftly that will demonstrate the synergistic advantages of our Gamma Delta T cell therapies in combination with existing anticancer treatment modalities. These submissions will expand the total number of our product candidate therapies to five. The first of these three new IND submissions - the Deltacel™ - is expected to be submitted during the second half of the year,” stated Pietro Bersani, Chief Executive Officer of Kiromic BioPharma. “Importantly, we expect to begin the activation of the Deltacel clinical trial by the end of this year. We believe utilizing non-genetically engineered Gamma Delta T cells as our first-in-human study is ideal to establish the tolerability and safety of our proprietary allogeneic cell therapy platform.”

In addition to Deltacel/KB-GDT - Kiromic’s non-engineered Gamma Delta T cells that are expanded, enriched and activated through a proprietary method - the second IND is expected to focus on Procel/KB-PD1, a genetically engineered product candidate targeting PD-L1+ tumors. The third IND is expected to focus on Isocel/KB-ISO, a genetically engineered product candidate targeting mesothelin isoform 2+ tumors. This isoform of mesothelin is a tumor-specific target identified by Kiromic’s proprietary DIAMOND AI bioinformatics platform.

The SRA and the anticipated filing of the three IND applications described above will expand Kiromic’s therapeutic pipeline to five allogeneic GDT clinical trials as follows:

Deltacel in combination with a standard antitumor modality
Procel in combination with a standard antitumor modality
Isocel in combination with a standard antitumor modality
Procel as monotherapy
Isocel as monotherapy
About Kiromic BioPharma

Kiromic BioPharma is a clinical-stage biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology and other diseases. Kiromic is in the process of developing a multi-indication gamma delta allogeneic T cell therapy treatment platform that exploits the natural potency of gamma delta T cells to target solid cancers. Kiromic is focused on discovering, developing and commercializing novel immuno-oncology therapies through its robust product pipeline, leveraged by DIAMOND® AI, a proprietary target discovery engine where data science meets target identification to dramatically compress the timeline and cost of drug development. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005593/en/

Kiromic BioPharma
Linda Phelan Dyson, MPH, Global Head, Corporate Communications
281-468-7683
[e-mail]

LHA Investor Relations
Tirth T. Patel
212-201-6614
[e-mail]